業界人士翹首以盼的第十八屆北京分析測試學術報告會暨展覽會(BCEIA2019)將于2019年10月23-26日在北京•國家會議中心舉行。本屆展會將繼續堅持“分析科學 創造未來”的方向，圍繞“生命 生活 生態——面向綠色未來”的主題組織學術報告會、專題論壇和儀器展。

同期將舉辦“BCEIA·2019——分析檢測與體外診斷國際高峰論壇”。該論壇將借助BCEIA平臺及中國分析測試協會影響力，為業內專家、學者、企業管理者、醫學研究和臨床檢驗技術人員提供充分探討交流的契機，凝心聚力、共同探索未來發展，助力人類健康事業的蓬勃發展。

近年來，隨著人類生活水平的提高和健康意識的增強，生命科學呈現高速發展的態勢，體外診斷作為生命科學及臨床醫學領域發展最快的細分領域之一，市場規模不斷擴大。據相關數據統計，2018年全球體外診斷的市場規模達到了800億美元左右，其中中國的市場規模約為500億人民幣左右，以每年15%的增速增長，其增速遠高于國際市場同期。

中國體外診斷行業的高速發展和中國龐大的人口基數、經濟水平的提升，人口流動的加大、新發傳染病的增加、人們健康意識的增強和國家對醫療行業、生物技術產業化發展的重視密不可分。在體外診斷行業巨大的市場效應推動下，分析科學的發展也越來越多地向體外診斷領域聚焦，質譜、數字PCR等分析技術的應用更加廣泛，在癌癥、神經系統疾病等早期篩查中發揮了越來越重要的作用。

分析技術飛速發展，檢測方法日新月異，質譜檢測平臺已經成為臨床醫學檢驗的熱點，在微生物鑒定、新生兒篩查、腫瘤標志物的鑒定方面起到了舉足輕重的作用。電化學發光技術是結合免疫技術、抗體技術、生物技術的新型的分析測試技術，該技術靈敏度高、穩定性好、重復性好，自動化程度高，便于被臨床和檢驗人員接受，能為病人和醫院提供準確的、大批量的結果，在臨床檢測中有著廣泛的應用。均相免疫分析技術是在結合小分子抗體技術和酶學之上發展出來的，不受樣品影響，解決了大批量臨床檢測需求，在腫瘤、代謝、內分泌方面有良好的應用。這些新技術結合抗體和標記技術的使用，最終能對臨床樣本進行快速高效檢測，為臨床提供準確可靠的檢測結果，擴大了分析技術的使用范圍。

分析檢測與體外診斷國際高峰論壇特邀國內外相關交叉領域的知名專家，對分析檢測儀器和技術在體外診斷領域的應用及發展趨勢進行專業及深入的討論。

嘉賓主持人、特邀報告人

嘉賓主持人：劉虎威

劉虎威，博士。北京大學化學與分子工程學院教授。分別于1982年和1990年在北京理工大學獲得學士和博士學位。然后加盟北京大學，1985年成為副教授，2001年成為教授。他的研究興趣是生物分離與檢測，包括色譜、毛細管電泳和質譜，以及聯用技術如LC-MS,CE-MS。應用領域包括藥物分析、植物激素檢測，蛋白組學和脂質組學分析。迄今已發表學術論文280余篇，3部著作，還為10本書籍撰寫了章節。目前是中國化學會和美國化學會會員，兼任中國質譜學會副理事長、中國化學會色譜專業委員會副主任、中國分析測試協會副秘書長。Journal of Separation Science 和 Journal of Analysis and Testing副主編，色譜責任副主編。他還是Analytical Chemistry(2013-2015), Analytical and Bioanalytical Chemistry, Molecules (Section Board for Analytical 英文版、質譜學報、現代科學儀器、現代儀器與醫療、巖礦測試和食品安全質量檢測學報編委。全國科學技術名詞審定委員會化學名詞審定委員會委員。全國儀器分析測試標準化技術委員會委員。×Chemistry)，以及化學通報、分析試驗室、分析測試學報、分析科學學報、中國藥學

特邀主旨報告人：詹啟敏

詹啟敏，北京大學常務副校長、醫學部主任。中國工程院院士，教授，博士生導師。教育部長江學者，國家杰出青年基金獲得者，新世紀百千萬人才工程國家級人選，國家自然科學基金委創新群體首席專家，國家973重大基礎研究項目首席科學家。

擔任中國醫師協會副會長、中國抗癌協會副理事長、中國微循環學會副理事長兼秘書長、歐美同學會海外醫師協會會長。先后擔任國家863高技術計劃生物和醫藥領域專家組組長和生物醫藥主題組組長，國家新藥創制重大專項生物藥責任專家組組長，國家衛生計生委行業科技專項委員會主任，國家生物醫藥技術戰略發展規劃專家組組長，國家健康保障科技工程專家組組長，國家生物技術發展戰略指導專家委員會主任。

長期致力于腫瘤分子生物學和腫瘤轉化醫學研究，在國際上率先發現和系統揭示了細胞周期監測點關鍵蛋白的作用和機制，闡明多個重要細胞周期調控蛋白在細胞癌變和腫瘤診斷與個體化治療中的作用。近年來，在基因組水平全面系統的揭示了食管癌的遺傳突變背景，為了解食管癌的發病機理、尋找食管鱗癌診斷的分子標志物、確定研發臨床治療的藥物靶點提供了理論和實驗基礎。3次擔任國家973項目首席科學家(15年)，2次承擔國家基金委重點項目，承擔國家基金委重大項目和創新群體項目(9年資助)，發表SCI學術論文240多篇，包括 Nature，Cell, J Clin Invest, EMBO, Mol Cell Biol, Science, Cancer Res, Oncogene, J Biol Chem and PNAS, 發表科技論文的SCI引用14000多次，主編著作5部。應邀在國內外學術會議上作大會報告120余次，11次擔任國際(雙邊)會議共同主席。

特邀主旨報告人：謝曉亮

謝曉亮，生物物理化學家，美國國家科學院院士、美國國家醫學院院士、美國藝術與科學院院士、中國科學院外籍院士。1962年生于北京，1984年本科畢業于北京大學化學系，1990年在美國加州大學圣地亞哥分校獲博士學位，在芝加哥大學完成博士后研究后到美國太平洋西北實驗室工作。1998年被哈佛大學聘為化學和化學生物系終身教授，2009-2018年任哈佛Mallinckrodt講席教授?，F任北京大學李兆基講席教授，北京大學生物醫學前沿創新中心主任，北京未來基因診斷高精尖創新中心主任。

謝曉亮是單分子酶學的創始人、單分子生物物理化學的奠基人之一、相干拉曼散射顯微成像技術和單細胞基因組學的開拓者。

特邀主旨報告人：曾映

曾映，深圳普門科技股份有限公司常務副總裁，全面負責深圳普門科技股份有限公司研發工作。

普門公司體外診斷事業部開發出了電化學發光免疫分析系統、免疫比濁分析系統、側向流免疫熒光分析系統、高效液相糖化血紅蛋白分析系統和血栓彈力圖分析系統。免疫比濁分析系統獲得了深圳市科學技術進步一等獎。

普門公司治療產品事業部開發的創面治療解決方案獲得了國家科學技術進步一等獎。

曾映先生也曾經在通用電氣中國有限公司醫療系統和深圳邁瑞生物醫療電子股份有限公司工作近二十年。

特邀主旨報告人：Emmanuelle Claude

Emmanuelle Claude女士(精細化學和商業碩士,有機化學和生物光譜學分析碩士), 2000年10月開始在Waters 公司擔任蛋白質組學和基因組學的應用工程師，使用MALDI-TOF質譜儀開發自動化多肽指紋圖譜(PMF)的方法。

多年來，她利用MALDI-TOF在蛋白質組學分析領域開發了許多方法，并在12年前開始在Waters公司開發質譜成像技術(MSI)。

她參與了硬件和軟件的研發，以確保這些解決方案適合質譜成像的用戶。她曾與歐洲和美國的主要質譜成像技術領導人廣泛合作，如荷蘭的Heeren教授、克倫奇教授、英國的Takats教授和邦奇教授以及美國的Caprioli教授。她自2014年起擔任首席科學家，負責管理沃特世的質譜成像應用團隊，該團隊為市場部(即應用文獻、客戶演示、論文、海報等)生成數據，并為研發團隊設定硬件和軟件需求。該團隊為MALDI和DESI評估和開發新的應用和方法。

特邀主旨報告人：虞留明

虞留明先生是蘇州博源醫療科技有限公司(簡稱“博源醫療”)的董事長兼CEO，他在研發均相酶免疫法(HEIA)小分子檢測領域享有聲望。在創立博源醫療之前，虞先生曾擔任美國奎斯特診斷公司(Quest Diagnostic)的研發總監，奎斯特診斷是全球最大的第三方檢測中心。他也曾是美國病理學家協會(College of American Pathologists，CAP)中國質量大使和檢察官，CAP被國際公認為實驗室質量保證的領導者和權威性的實驗室管理和認證組織。自2012年創立博源醫療至今，虞先生已帶領公司研發團隊成功研發100多種HEIA試劑，獲得了30多個國家發明專利授權，并成功獲得12個HEIA試劑的注冊證。其研究成果得到政府支持和認可，曾獲“國家火炬計劃”、“江蘇省科技成果獎”、“江蘇省雙創獎”、“蘇州領袖獎”等多項地方性和國家級獎項。2013年，博源醫療成為國內首家開發出HEIA技術的IVD公司。近幾年來，HEIA產品已得到國內眾多臨床實驗室的廣泛認可。HEIA檢測分析物覆蓋廣泛的臨床標志物，包括：治療藥物監測(TDM)、內分泌、代謝物、濫用藥物(DOA)和摻假物。

會議日程

時間	內容	報告人
8:30-9:30	會議簽到
9:30-9:40	開幕詞	劉虎威 教授 北京大學
09:40-10:10	綜述報告-科技創新與醫院展望	詹啟敏 教授 中國工程院院士 北京大學
10:10-10:40	單細胞組學：解碼人類基因組	謝曉亮 教授 美國國家科學院院士 北京大學
10:40-11:10	電化學發光免疫分析及臨床應用	曾映 常務副總裁 深圳普門科技股份有限公司
11:10-11:20	茶歇
11:20-11:50	質譜成像技術在生物醫學研究上的進展	Emmanuelle Claude 博士 首席科學家（健康科學） 美國沃特世公司（Waters）
11:50-12:20	均相酶免疫（HEIA）技術在小分子檢驗中的應用	虞留明 董事長及CEO 蘇州博源醫療科技有限公司
12:20-12:30	閉幕致辭	劉虎威 教授 北京大學

舉辦時間地點

會議名稱：分析檢測與體外診斷國際高峰論壇

會議時間：2019年10月23日 上午 9:30-12:45

會議地點：北京北辰洲際酒店

會議語言：中文、英文

論壇定位

國際化、專業化、跨行業、高層次

論壇目的

展示業內最前沿的研究與技術，最先進的理念、最大膽的構想。為行業內專業人士提供對話與交流的平臺，探討分析測試技術在體外診斷領域的現在與未來

論壇形式

綜述報告+主題演講

組織單位

中國分析測試協會

聯系人

王勵英

電話：010-68512289

掃描上方二維碼，點擊報名，

即可預約參會，名額有限，先報先得

關于BCEIA：

北京分析測試學術報告會暨展覽會(BCEIA)由中國分析測試協會主辦，自1985年舉辦第一屆以來，秉持“分析科學創造未來”的發展方向，吸引了來自20多個國家廠商參展，參會人員來自多達30多個國家和地區，參會人數達25000余人，其中學術報告會注冊專家3400余名，是我國分析測試領域專業化程度最高的國際性盛會。

BCEIA2019 International Summit on Analytical
Instrumentation and In Vitro Diagnosis

--Registration in Progress

In recent years，In Vitro Diagnosis has become one of the fastest growing segments in the field of life sciences and clinical medicine worldwide. Statistics reveal that in 2018, the size of the global InVitro diagnosis market reached USD 80 billion while the Chinese market reached RMB 50 billion, representing an annual growth of 15%.

The rapid growth in the Chinese InVitro diagnosis market is driven by China's large population, the substantial growth of the economy, great population mobility, the increase in emerging infectious diseases，enhancement of people's awareness about health and the Government's development initiatives regarding the healthcare industry and biotechnology industrialization.

Market factors are driving the development of analytical sciences to focus more on InVitro diagnosis, and as a result, the usage of some analytical technologies such as mass spectrometers and digital PCR are experiencingincreasedusage in the early screening of cancer and nerve system diseases.

Analytical technology and testing methods are developing at an everincreasing speed. Mass spectrometry platforms have become the spotlight of Clinical medical examination, especially in microorganismidentification, neonatal screening and identification of tumor markers. Electrochemiluminescence technology is a new testing technology based on immunological technique, antibody technology and biotechnology, which has gained extensive application in clinical detection thanks to its characteristics of high sensitivity, strong stability, good repeatability and a highdegreeofautomation.

Small Molecule Testing has always been a strength of analytical technology but has been limited by various conditions of samples, and sample pre-treatment is always required. Based on the small molecule antibody technology and enzymology, Homogeneous Enzyme Immunoassay (HEIA) technology was developed to overcome the limitations on sample influences, and hence resolve the problem of mass clinical testing requirements. HEIA technology is well applied in tumors, metabolism and internal secretion diseases, and clinical sample testing has improved in terms efficiency and accuracy.

The “International Summit on Analytical Instrumentation and InVitro Diagnosis” specially invites renowned interdisciplinary experts to participate in debates on the development and application of analytical instruments and technology in the field of InVitro diagnosis, and the perspective of human health. The Summit will be one of the highlight events of BCEIA 2019.

International Summit on Analytical Instrumentation

and In Vitro Diagnosis

Agenda

Date: 23October, 2019 (09:30-12:45)

Location: InterContinental Beijing Beichen, China

Language: Chinese and English

Time	Content	Speaker
8:30-9:30	Registration
9:30-9:40	Opening Speech	Huwei Liu Professor Peking University
09:40-10:10	Overview Report-Technology Innvoation and Hospital Developmen	Qimin Zhan Professor Academician of CAE Peking University
10:10-10:40	Single Cell Omics: Decoding Human Genome	Xiaoliang Sunney Xie Professor Academician of NAS, United States Peking University
10:40-11:10	Electrochemiluminescence Immunoassay and Its Application	Ying Zeng EVP Lifotronic Technology Co, Ltd
11:10-11:20	Coffee Break
11:20-11:50	Advancements in MS imaging for Biomedical Research	Emmanuelle Claude Principal Scientist（Health Sciences Business） Waters Corporation
11:50-12:20	Applications of Homogeneous Enzyme Immunoassay (HEIA) for Small Molecule Testing	Liuming Yu Chairman& CEO Suzhou Evermed Biomedical Co, Ltd
12:20-12:30	Closing Speech	Huwei Liu Professor Peking University

Guest Moderator

Huwei Liu

Huwei Liu is the Ph.D. Professor of Institute of Analytical Chemistry, College of Chemistry and Molecular Engineering, Peking University.

Dr. Huwei Liu graduated with a BA degree in 1982, and Ph·D·in 1990 from Beijing Institute of Technology (BIT), China, then he joined Peking University, became a full professor in 2001. His research work focuses on bioseparation and detection, including fundamentals and applications of chromatographic, electrophoretic separation techniques and mass spectrometry, as well as hyphenated methods such as LC-MS and CE-MS. The application areas cover pharmaceutical analysis, plan hormone detection, proteomics and lipidomics analysis. He is the author and co-author of more than 280 research papers and reviews, 3 books, and several chapter contributions of the edited books. He is currently a member of Chinese Chemical Society and American Chemical Society, a vice president of China Mass Spectrometry Society, president of Beijing Chromatography Society. Reputy Secnetany General of China Association for Instrumental Analysis (CAIA). He also serves as an associate editor of Journal of Separation Scienceand Journal of Analysis and Testing, an executive editor of Chinese Journal of Chromatography, an advisory/editorial board member for Analytical Chemistry(2013-2015), Analytical and Bioanalytical Chemistry, Molecules (Section Board for 'Analytical Chemistry') and other ten Chinese journals.

Keynote Speakers

Qimin Zhan, MD

Qimin Zhan, MD, is currently an Academician of the Chinese Academy of Engineering, the Executive Vice President of Peking University, President of Peking University Health Science Center, President of Peking University Shenzhen Graduate School, and the Director of the State Key Laboratory of Molecular Oncology.

Dr. Zhan is the chairman of National Health Care Project and the chairman of National Biotechnology Development Strategy. He was the Chairman of the National Advisory Board for 863 High-Tech plan in the field of biomedical sciences and is the Chief Scientist of the 973 National Fundamental Program. Dr. Zhan’s research interest is focused on the molecular pathways involved in the control of cell cycle checkpoint and apoptosis after DNA damage, and the signaling pathways involved in regulation of the maintenance of genomic stability and tumor metastasis. In recent years, Dr. Zhan has paid great attention to the cancer translational study, including molecular diagnosis and personalized therapy. His research has successfully attracted multiple grants from different funding agencies. Dr. Zhan’s has published more than 240 peer-reviewed SCI papers. Many of his publications are in prestigious journals, including Nature, Cell, the Journal of Clinical Investigation, and others. To date, they have been cited more than 14,000 times.

Xiaoliang Xie

Professor Xie is an internationally renowned biophysical chemist, and the Lee Shao-kee professor of Peking University. After a career at Pacific Northwest National Laboratory, he became the first tenured professor at Harvard University among Chinese scholars who went to the US since the Reform in China. As a pioneer of single-molecule biophysical chemistry, coherent Raman scattering microscopy, and single-cell genomics, he made major contributions to the emergence of these fields. In particular, his inventions in single-cell genomics have been used in in vitro fertilization to benefit hundreds of couples in China by avoiding the transmission of monogenic diseases to their newborns.

Ying Zeng

Mr. Zeng is the EVP of Lifotronic Technology Co., Ltd., who is in charge of the Research and Develop Department of the company.

IVD Division of Lifotronic has developed an electrochemiluminescence immunoassay system, a nephelometer immunoassay system, a lateral flow immunofluorescence analysis system, a HPLC HbA1c analysis system and a thrombelastogram analysis system. The nephelometer immunoassay system has won the first prize of the progress of science and technology in Shenzhen.

Healing products Division of Lifotronic developed wound treatment solutions, have won the first prize of the national award of the progress of science and technology.

Mr. Zeng has also worked in GE Healthcare,China and Shenzhen Mindray Biomedical Electronics Co., Ltd for nearly 20 years.

Emmanuelle Claude

Miss Emmanuelle Claude (Master in Fine Chemistry and Business and P.Phil in spectroscopy analysis in organic chemistry and biology) has started at Waters Corporation in October 2000 as an Application Chemist in the Proteomics and Genomics Marketing group, developing automated Peptide Mass Fingerprint (PMF) MS methods using a MALDI-TOF mass spectrometer.

Over the years she developed a number of methods in the proteomics analytical space using MALDI TOF and naturally moved in starting the development of Mass Spectrometry Imaging (MSI) at Waters corporation over 12 years ago.

She has been involved with hardware and software R&D to ensure that the solutions were fit-for-purpose for the MSI community. She has worked extensively with the main MSI leaders in Europe and the US such as Prof Heeren in the Netherlands, Prof Clench, Prof Takats and Bunch in the UK and Prof Caprioli in the US. She has been a Principal Scientist since 2014 and is managing the MS imaging application team at Waters where data are generated for marketing (i·e·application literature, customer presentation, papers, posters...), hardware and software requirements are defined for the R&D teams. The team evaluates and develops new applications & methods for Imaging by both MALDI and DESI mass spectrometry。

Liuming Yu

Mr. Yu is the Chairman & CEO of Suzhou Evermed Biomedical Co., Ltd (“Evermed”). He is a well-known expert in development of liquid reagents for measurement of small molecules using Homogeneous Enzyme Immunoassay (HEIA) methodology. Prior to his tenure at Evermed he held a prestigious position as the R&D Director at Quest Diagnostic, the largest reference laboratory in the world. He also served as the inspector and the Chinese ambassador of CAP (College of American Pathologists). Since founding Suzhou Evermed in 2012 he headed his company to develop more than 100 HEIA assays, acquired more than 30 China invention patents, and successfully received cFDA approvals for twelve clinical HEIA products. His achievements were recognized and won multiple local and national awards including: “National Torch Plan”, “Jiangsu Science and Technology Achievement”, “Jiangsu Double-Creation Reward”, and “Suzhou Leadership Award”. In 2013 Evermed was the first IVD company in China to utilize the HEIA methodology for clinical diagnostic testing. Within a few years, HEIA products have been widely accepted by many clinical laboratories in China. Tested analytes include a broad range of clinical markers covering: Therapeutic Drug Monitoring (TDM), Endocrines, Metabolites, Drugs of Abuse (DOA), and Adulterants.

Contact Person

Ms. Liying Wang

Phone:+86-10-6851 2289

E-mail: liying.wang@caia.org.cn

Register Here

Scan the QR code

About BCEIA:

Sponsored by CAIA (China Association for Instrumental Analysis), the Beijing Conference and Exhibition on Instrumental Analysis (BCEIA) is a highly specialized and well respected international analytical instruments conference and exhibition in China. After being held for and developed over 30 years, BCEIA is becoming more renowned worldwide, with exhibitors and participants coming from over 20 and 30 countries respectively, to participate in the great event on a biennial basis. In 2017 the number of registered participants exceeded 25,000, and the registered experts for the Academic Conference reached 3,400.

The 18th Beijing Conference and Exhibition on Instrument Analysis (BCEIA2019) is scheduled to be held from 23rd to 26th October, 2019 at the China National Convention Center, Beijing, China. With the vision of “Analytical Science Creates Future”, BCEIA 2019 will continue to host academic conferences, summits, forums and exhibition under the theme of “Moving Towards a Green Future”.